[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study

Purpose: To characterise efficacy and safety of (177)Lu-DOTATOC as agent for peptide receptor radiotherapy (PRRT) of advanced neuroendocrine tumours (NET). Patients and methods: Fifty-six subjects with metastasized and progressive NET (50% gastroenteral, 26.8% pancreatic, 23.2% other primary sites)...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Richard P., Kluge, Andreas W., Kulkarni, Harshad, Schorr-Neufing, Ulrike, Niepsch, Karin, Bitterlich, Norman, van Echteld, Cees J.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775860/
https://www.ncbi.nlm.nih.gov/pubmed/26941843
http://dx.doi.org/10.7150/thno.13702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775860/
https://www.ncbi.nlm.nih.gov/pubmed/26941843
http://dx.doi.org/10.7150/thno.13702

Ejemplares similares